首页 Cormedix(usCRMD)-基本信息

Cormedix(usCRMD)-基本信息

日报更新时间:

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

英文名称:Cormedix


简介:Cormedix Inc.是于2006年7月28日在美国特拉华州注册成立


电话:1-908-5179500


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

CorMedix Inc.是一家生物制药公司,致力于开发和商业化用于预防和治疗传染病和炎症性疾病的治疗产品。CorMedix公司致力于开发其主要产品Neutrolin®,这是一种新型非抗生素抗菌解决方案,旨在预防与中心静脉导管相关的昂贵且危险的血流感染,目前正在进行 III 期临床试验,招募接受慢性血液透析的患者。这种感染每年花费美国医疗保健系统大约60亿美元,并且显着增加了发病率和死亡率。Neutrolin具有FDA快速通道,被指定为合格的传染病产品,可提供FDA优先审核的潜力,如果获得在美国批准销售,将获得五年的QIDP市场独占(专利保护)。Neutrolin®已经在欧洲和其他地方上市。与此同时,CorMedix正在利用其taurolidine(牛磺罗定)技术开发出一系列抗菌医疗设备,其中包括手术缝合线和网状物以及局部水凝胶的活跃程序。此外,CorMedix公司还与顶级研究人员合作,为罕见的儿科癌症开发基于taurolidine的疗法。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-11 Dunton (Alan W) Director Buy 1250 --
2019-05-14 Dillione (Janet M) Director Buy 11144 6.74
2019-03-28 Cook (Robert W.) Chief Financial Officer Buy 100 9.35
2019-03-25 Armstrong (John L Jr) Officer Buy 5000 7.73
2019-03-25 Baluch (Khoso) Chief Executive Officer Buy 2500 7.55
2019-03-24 Armstrong (John L Jr) Officer Buy 15000 1.69
2019-03-17 Dillione (Janet M) Director Buy 42000 1.67
2018-12-30 Armstrong (John L Jr) Officer Buy 18029 --
2018-12-19 Lefkowitz (Steven W) Director Buy 20000 1.18
2018-12-19 Khan (Mehmood) Director Buy 100000 1.24
2018-12-13 Kaplan (Myron) Director Buy 50000 1.47
2018-12-04 Masson (Elizabeth) Officer Buy 40000 0.29
2018-11-28 Armstrong (John L Jr) Officer Buy 250000 1.45
2018-11-26 Baluch (Khoso) Chief Executive Officer Buy 21500 1.21
2018-11-26 Cook (Robert W.) Chief Financial Officer Buy 25000 1.17
2018-11-25 Baluch (Khoso) Chief Executive Officer Buy 3500 1.28
2018-11-22 Kaplan (Myron) Director Buy 50000 1.30
2018-11-05 Kaplan (Myron) Director Buy 5000 --
2018-10-11 GELBFISH GARY A Director Sell 468750 2.24
2018-10-11 GELBFISH GARY A Director Buy 1000000 1.05
2018-09-30 Lefkowitz (Steven W) Director Buy 10000 --
2018-02-20 Kaplan (Myron) Director Buy 10000 --
2018-02-20 Dillione (Janet M) Director Buy 15357 --
2018-02-15 Khan (Mehmood) Director Buy 12500 --
2018-02-15 GELBFISH GARY A Director Buy 10000 --

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Northern Trust Investments N A 44628 0.19% -999 -2.19% 2019-03-31
Geode Capital Management, LLC 157773 0.66% 157773 -- 2019-03-31
Fidelity Management & Research Company 162759 0.68% 11069 7.30% 2019-07-31
Millennium Management LLC 230923 0.97% 225125 3882.80% 2019-03-31
BlackRock Inc 421602 1.77% -109732 -20.65% 2019-03-31
Vanguard Investments Australia Ltd 573586 2.41% -- -- 2019-07-31
BlackRock Fund Advisors 809430 3.40% 1012 0.13% 2019-07-31
Elliott Management Corp 833373 3.50% -1 -- 2019-03-31
Vanguard Group Inc 921422 3.87% 93678 11.32% 2019-03-31
EAM Investors, LLC 146472 0.62% 27587 23.20% 2019-03-31
Goldman Sachs Group Inc 123695 0.52% 123695 -- 2019-03-31
BlackRock 106701 0.45% 61398 135.53% 2019-07-31
Northern Trust Corp 44628 0.19% -999 -2.19% 2019-03-31
BlueCrest Capital Management Ltd. 45231 0.19% 45231 -- 2019-03-31
Tibra Equities Europe Ltd 62791 0.26% 62791 -- 2019-03-31
BlackRock Institutional Trust Company NA 63136 0.27% 63136 -- 2019-07-31
Bridgeway Capital Management, Inc 68500 0.29% 68500 -- 2019-03-31
Spinnaker Capital LLC 80384 0.34% -- -- 2019-03-31
Northern Trust Investments Inc 85690 0.36% 29997 53.86% 2019-07-31
EAM Global Investors, LLC 99437 0.42% 99437 -- 2019-03-31
Bank of America Corporation 42881 0.18% 41856 4083.51% 2019-03-31
Catalyst Capital Advisors LLC 40800 0.17% 40800 -- 2019-03-31
Franklin Resources Inc 37894 0.16% 2235 6.27% 2019-03-31
Steward Partners Investment Advisory, LLC 38278 0.16% 22500 142.60% 2019-03-31
BlackRock Advisors (UK) Ltd 31884 0.13% 31884 -- 2019-03-31
Barclays PLC 31998 0.13% 31998 -- 2019-03-31
K2/D&S Management Co., L.L.C. 178295 0.15% 7827 4.59% 2018-12-31
Bank of New York Mellon Corp 150689 0.13% 113029 300.13% 2018-12-31
Mellon Investments Corporation 21943 0.09% 3176 16.92% 2019-04-30
Principal Global Investors, LLC 26371 0.11% 26371 -- 2019-04-30
BNY Mellon Investment Management 150689 0.13% 113029 300.13% 2018-12-31
Group One Trading, LP 78135 0.07% 77389 10373.86% 2018-12-31
Wells Fargo & Co 105842 0.09% 105842 -- 2018-12-31
Planning Directions Inc 107409 0.09% -- -- 2018-12-31
Private Advisor Group, LLC 73034 0.06% 1294 1.80% 2018-12-31
State Street Corporation 68247 0.06% 53500 362.79% 2018-12-31
Virtu Financial LLC 394051 0.37% 206099 109.66% 2018-09-30
Susquehanna Financial Group, LLLP 73582 0.07% 73582 -- 2018-09-30
Susquehanna International Group, LLP 73582 0.07% 73582 -- 2018-09-30
Atlantic Trust Group, LLC 60000 0.06% 30000 100.00% 2018-09-30
HighTower Advisors, LLC 48188 0.04% 1000 2.12% 2018-09-30
Analytic Investors, LLC 41346 0.04% 41346 -- 2019-01-31
Franklin Advisers, Inc. 170468 0.16% -52786 -23.64% 2018-09-30
Citadel Advisors Llc 41661 0.04% -211158 -83.52% 2018-06-30
The Variable Annuity Life Insurance Company 40000 0.04% -- -- 2018-10-31
Sabby Management LLC 3344568 4.68% -1788764 -34.85% 2017-12-31
Elliott Associates LP 1333398 1.99% 1333398 -- 2017-11-09
Franklin Advisers Inc 223254 0.26% 15891 7.66% 2018-06-30
TWO SIGMA SECURITIES, LLC 78819 0.09% 78819 -- 2018-03-31
Taurus Asset Management, LLC 30000 0.03% -- -- 2018-06-30
Washington Trust Co 24750 0.03% -- -- 2018-03-31
State Street Corp 17767 0.02% -- -- 2018-06-30
Morgan Stanley Smith Barney LLC 14000 0.01% -- -- 2018-06-30
UBS Securities LLC 28700 0.03% -34254 -54.41% 2018-03-31
Commonwealth Equity Services Inc 16386 0.02% -- -- 2017-12-31
Brandes Investment Partners & Co 85000 0.12% 85000 -- 2017-12-31
Bt Alex Brown Inc 51600 0.07% 51600 -- 2017-12-31
Merrill Lynch & Co Inc 32000 0.04% 5000 18.52% 2017-12-31
Mellon Capital Management Corporation 24944 0.04% 24944 -- 2017-12-31
Nine Chapters Capital Management LLC 42400 0.07% 42400 -- 2017-09-30
Ray Gerald L & Associates Ltd 57000 0.09% -70000 -55.12% 2017-09-30
Bollard Group LLC 401920 0.65% -- -- 2017-09-30
Hudson Bay Capital Management LP 791632 1.33% 791632 -- 2017-06-30
Spot Trading LLC 69600 0.17% 69600 -- 2016-09-30
Goldman, Sachs & Co. 78817 0.20% 4425 5.95% 2016-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
NT Ext Equity Market Index Fund - L 20635 0.09% -- -- 2019-06-30
Fidelity 45353 0.19% 11069 32.29% 2019-06-30
Schwab Small Cap Index Fund 49061 0.21% 49061 -- 2019-06-30
iShares Micro-Cap ETF 59881 0.25% -- -- 2019-07-30
Bridgeway Ultra Small Company Market Fd 66000 0.28% 66000 -- 2019-03-31
iShares Russell 2000 Growth ETF 213616 0.90% -- -- 2019-07-30
Vanguard Extended Market Index Fund 333721 1.40% 783 0.24% 2019-06-30
iShares Russell 2000 ETF 514264 2.16% 1012 0.20% 2019-07-30
Vanguard Total Stock Market Index Fund 573586 2.41% -- -- 2019-06-30
BlackRock Extended Equity Market 45242 0.19% -61 -0.13% 2019-06-30
Catalyst Small Cap Insider Buying Fund 40800 0.17% 40800 -- 2019-03-31
Vanguard Russell 2000 Index Fund 21369 0.09% 21369 -- 2019-06-30
BlackRock Russell 2000 22979 0.10% 22979 -- 2019-06-30
BlackRock Russell 2500 23913 0.10% 23913 -- 2019-06-30
Vanguard Instl Total Stock Market Idx Fd 25705 0.11% -- -- 2019-06-30
iShares Russell 2000 Small-Cap Index Fd 26390 0.11% 26390 -- 2019-06-30
LVIP SSgA Small Cap Index Fund 29200 0.12% 29200 -- 2019-06-30
The Vanguard - Russell 2000 Grwth Idx CF 33163 0.14% 33163 -- 2019-06-30
Russell 2000 Index Non-Lendable Fund E 34748 0.15% 34748 -- 2019-06-30
Mandarine Global Microcap 20000 0.08% 20000 -- 2019-03-31
NT Extended Equity Market Idx Fund - NL 18899 0.08% -- -- 2019-06-30
Principal Healthcare Innovators ETF 18285 0.08% -- -- 2019-06-30
BNYM Mellon NSL Mkt Completion Fd Instl 16966 0.07% 15720 1261.64% 2019-03-31
Northern Small Cap Core Fund 15200 0.06% 15200 -- 2019-06-30
Vanguard Balanced Index Fund 14815 0.06% -- -- 2019-05-31
NT Ext Equity Mkt Fd - DC - NL 12539 0.05% -221 -1.73% 2019-03-31
SPDR 12635 0.05% -- -- 2019-06-28
State Street U.S. Extended Market Index 13508 0.06% -- -- 2019-05-31
Principal US Small Cap Mlt Fac Ind ETF 8086 0.03% -- -- 2019-05-31
Wells Fargo Factor Enhanced Sm Cp IdxCIT 7031 0.03% -1239 -14.98% 2019-03-31
Schwab Total Stock Market Index Fund 5920 0.02% -- -- 2019-05-31
iShares Core S&P Total US Stock Mkt ETF 5248 0.02% 13 0.25% 2019-06-26
NT Ext Equity Mkt Idx Fd - DC - NL 12539 0.05% -221 -1.73% 2019-03-31
iShares Core S&P US Total Market ETF 5038 0.02% -- -- 2019-05-30
Vanguard US Equity Index Fund 4880 0.02% -- -- 2019-04-30
BNYM Mellon SL Mkt Completion Fd 4977 0.02% -12544 -71.59% 2019-03-31
USAA Extended Market Index Fund 7588 0.01% -- -- 2019-01-31
NT US Market Cap Index Fund - Lending 3358 0.01% -947 -22.00% 2019-03-31
Wells Fargo Factor Enhanced Small Cap 16947 0.01% -5891 -25.79% 2019-01-31
The Vanguard Total Stock Market Index 3798 0.02% 3798 -- 2019-03-31
Spartan Total Market Index Pool 19417 0.02% 19417 -- 2019-01-31
Wells Fargo Factor Enhanced Small Cp Fd 52 -- -8 -13.33% 2019-01-31
Esfera III Titan Dynamic FI 2000 -- -1000 -33.33% 2019-02-28
BNY Mellon Market Completion Fund 6231 0.01% -4940 -44.22% 2018-12-31
VALIC Company I Small Cap Fund -- -- -40000 -100.00% 2018-03-31
Master Extended Market Index Series -- -- -7588 -100.00% 2018-02-28
Vanguard Total Stock Mkt Idx 1253757 1.47% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 419187 0.49% 19400 4.85% 2018-07-31
Vanguard Balanced Index Inv 87680 0.10% -- -- 2018-07-31
Fidelity Spartan 48587 0.06% -- -- 2018-07-31
BlackRock Extended Equity Market K 77669 0.09% 2112 2.80% 2018-06-30
Vanguard Instl Ttl Stk Mkt Idx InstlPls 23800 0.03% -- -- 2018-07-31
iShares Core S&P Total US Stock Mkt 19015 0.02% -- -- 2018-09-12
BNY Mellon EB DL Mkt Completion 34707 0.04% -- -- 2018-06-30
USAA Extended Market Index 7588 0.01% -- -- 2018-07-31
BNY Mellon Market Completion Fund UC1 11171 0.01% 9614 617.47% 2018-03-31
SSgA U.S. Total Market Index Fd Class I 3920 0.01% -256 -6.13% 2017-12-31
VALIC Company I Small Cap 40000 0.06% -- -- 2018-02-28
Bridgeway Ultra-Small Company Market 127701 0.18% -50000 -28.14% 2017-12-31
iShares Micro-Cap 97409 0.30% -- -- 2017-02-07
AXA/Lord Abbett Micro Cap K 6317 0.02% -- -- 2016-11-30
State Street Russell Small Cap Growth Idx Cl A 2600 0.01% -- -- 2015-12-31
Marketocracy Masters 100 1600 -- -- -- 2016-12-31
BlackRock LifePath 27 -- 9 50.00% 2016-03-31
iShares Russell 2000 Growth 271676 0.80% -- -- 2015-11-27
Bridgeway Ultra Small Company Market 168001 0.50% 113001 205.50% 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 116216 0.30% -- -- 2015-10-31
CREF Stock Account 75434 0.20% -- -- 2015-09-30
AQR Small Cap Momentum Style Fund 71090 0.20% -- -- 2015-09-30
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 65842 0.20% -2900 -4.20% 2015-09-30
AXA 2000 Managed Volatility Portfolio 48639 0.10% 7502 18.20% 2015-09-30
Fidelity Spartan® Total Market Idx Fund 48587 0.10% -- -- 2015-10-31
BlackRock Russell 2000® Index Non-Lendable Fund 45653 0.10% 14234 45.30% 2015-09-30
Schwab Small Cap Index Fund® 45377 0.10% -- -- 2015-09-30
iShares Russell 2000 (AU) 555178 1.50% -339 -0.10% 2015-11-27

Myron Kaplan Currently, Myron Kaplan is Chairman for CorMedix, Inc. He is also on the board of JBI International, Inc. and Founding Partner of Kleinberg, Kaplan, Wolff & Cohen PC. Mr. Kaplan received an undergraduate degree from Columbia College Corp. and a graduate degree from Harvard Law School.
John L. Armstrong Presently, John L. Armstrong is EVP-Technical Operations & Head-Human Resources at CorMedix, Inc. Mr. Armstrong previously was President & Chief Executive Officer for Genaera Corp., President & Chief Operating Officer for Oread, Inc., President-Operations at Correvio LLC, Chief Executive Officer of Mills Biopharmaceuticals LLC, President-ENDO Laboratories at DuPont Merck Pharmaceutical Co., Vice President-Operation at Marion Merrell Dow, Inc. and Senior Vice President-Business Development for UroCor, Inc. John L. Armstrong received an MBA from Century College and an undergraduate degree from Juniata College.
Steven W. Lefkowitz Founder of Wade Capital Corp., Steven W. Lefkowitz is on the board of CorMedix, Inc., AIS RE Ltd. and Specialty Liquid Transportation Corp. In his past career he was President of Wade Capital Corp., Director at CorMedix, Inc., Vice President-Corporate Finance at Drexel Burnham Lambert, Inc. and Chairman of MEDCONX, Inc. Mr. Lefkowitz received an undergraduate degree from Dartmouth College and an MBA from Columbia Business School.
Mehmood A. Khan Mehmood A. Khan holds the position of Chief Executive Officer & Director at Life Biosciences LLC. He is also on the board of CorMedix, Inc., HemoShear LLC, Reckitt Benckiser Group Plc and Indigo Agriculture, Inc. and Fellow at American College of Endocrinology and Member of The Royal College of Physicians. He previously was Vice Chairman & CSO-Global Research & Development at PepsiCo, Inc., President at Takeda Global Research & Development Center, Inc., Chief Medical Officer at Takeda Pharmaceuticals U.S.A., Inc., Director-Diabetes & Endocrinology at The Mayo Clinic (Old) and Member of Mayo Medical School. Dr. Khan received a doctorate from The University of Liverpool.
Robert W. Cook Currently, Robert W. Cook is Chief Financial Officer for CorMedix, Inc. Mr. Cook previously was Chief Financial Officer & Executive Vice President for Pharmos Corp., Chief Financial Officer, Secretary & Treasurer for STRATA Skin Sciences, Inc., Chief Financial Officer, Director & Senior VP at Immune Pharmaceuticals, Inc. and President, CEO, CFO, Secretary & Director at EpiCept Corp. (a subsidiary of Immune Pharmaceuticals, Inc.), Managing Director at The Chase Manhattan Bank NA, Chief Financial Officer at Bioblast Pharma Ltd. and Vice President-Healthcare Group at GE Capital Commercial Finance, Inc. Robert W. Cook received an undergraduate degree from American University.
Alan W. Dunton Alan W. Dunton is a businessperson who founded Danerius LLC and who has been at the helm of 6 different companies. Currently, Dr. Dunton is Senior Vice President-Research & Development at Purdue Pharmaceuticals LP. He is also on the board of Palatin Technologies, Inc., Oragenics, Inc., CorMedix, Inc. and Cytogel Pharma LLC. In his past career he held the position of Chairman at Janssen Cilag International NV, President & Chief Executive Officer for Panacos Pharmaceuticals, Inc., President, Chief Operating Officer & Director at Emisphere Technologies, Inc., Head-Research & Development at Purdue Pharma LP, Chief Medical Officer for Adhera Therapeutics, Inc., Principal at Danerius LLC, Senior Executive at Johnson & Johnson President & Managing Director at The Janssen Research Foundation, VP-Global Clinical Research & Development at R.W. Johnson Pharmaceutical Research Institute and Member-Group Operating Committee at Johnson & Johnson Pharmaceutical Group (which are all subsidiaries of Johnson & Johnson), Non-Executive Chairman of EpiCept Corp., President & Chief Executive Officer for Metaphore Pharmaceuticals, Inc., Chief Medical Officer for Derma Sciences, Inc., Vice President-Clinical Research & Development at Syntex Corp., Vice President-Clinical Research & Development at Ciba-Geigy Corp. and Vice President-Clinical Research & Development at Hoffmann-La Roche, Inc. Alan W. Dunton received a doctorate from New York University School of Medicine and an undergraduate degree from State University of New York at Buffalo.
Andrew Robert John Bonfield Currently, Andrew Robert John Bonfield is Chairman of The Hundred Group of Finance Directors and Chief Financial Officer of Caterpillar, Inc. He is also on the board of Reckitt Benckiser Group Plc, National Grid Holdings One Plc and National Grid Holdings Ltd. In his past career Mr. Bonfield occupied the position of Executive Director & Finance Director at National Grid Plc, Chief Financial Officer & Executive Vice President of Bristol-Myers Squibb Co., Chief Financial Officer of Smithkline Beecham Plc, Finance Director of BG Group Ltd. and Chief Financial Officer for Cadbury Ltd. Andrew Robert John Bonfield received an undergraduate degree from University of Natal.
Antony E. Pfaffle Founder of CorMedix, Inc. and Black Diamond Research LLC, Antony E. Pfaffle holds the position of Secretary & Chief Scientific Officer at CorMedix, Inc. In his past career Dr. Pfaffle was Director-Healthcare Research at Bearing Circle Capital LP, Principal at Black Diamond Research LLC, Managing Director at Paramount BioCapital, Inc. and Senior Vice President-Business Development of Paramount BioSciences LLC (a subsidiary of Paramount BioCapital, Inc.), Analyst at BDR Research LLC, Medical Director at ParagonRx International LLC, Consultant at Memorial Sloan-Kettering Cancer Center and Faculty Member at New York University. Antony E. Pfaffle received a doctorate from New York Medical College.
Janet D. Dillione Currently, Janet D. Dillione is Chief Executive Officer of Bernoulli Enterprise, Inc. Ms. Dillione is also on the board of CorMedix, Inc. In the past she held the position of Executive Vice President & GM-Healthcare Division at Nuance Communications, Inc., Chief Executive Officer at Cardiopulmonary Corp. and President & CEO-Global Healthcare IT Division at Siemens Medical Solutions USA, Inc. Ms. Dillione received an undergraduate degree from Brown University.
Mehmood A. Khan Mehmood A. Khan holds the position of Chief Executive Officer & Director at Life Biosciences LLC. He is also on the board of CorMedix, Inc., HemoShear LLC, Reckitt Benckiser Group Plc and Indigo Agriculture, Inc. and Fellow at American College of Endocrinology and Member of The Royal College of Physicians. He previously was Vice Chairman & CSO-Global Research & Development at PepsiCo, Inc., President at Takeda Global Research & Development Center, Inc., Chief Medical Officer at Takeda Pharmaceuticals U.S.A., Inc., Director-Diabetes & Endocrinology at The Mayo Clinic (Old) and Member of Mayo Medical School. Dr. Khan received a doctorate from The University of Liverpool.
Mohammed Khoso Baluch Currently, Mohammed Khoso Baluch holds the position of Chief Executive Officer & Director at CorMedix, Inc. He is also on the board of Poxel SA. In the past he was Chairman at Ucb Pharma Sp zoo, Manager for UCB Pharma SA, Senior VP & President-EMEA Region at UCB SA Director & Senior Vice President at UCB, Inc. and Manager of Vedim Pharma SA (both are subsidiaries of UCB SA), Principal at Eli Lilly & Co., Chairman of UCB Pharma AB and Chairman at Ucb Pharma AS. He received an undergraduate degree from City University London and an MBA from Cranfield University.
John Ortiz John Ortiz holds the position of VP-Regulatory Affairs & Quality Assurance at CorMedix, Inc. In his past career Mr. Ortiz occupied the position of Head-Quality Assurance & Regulatory Affairs at Johnson & Johnson, Inc., Head-Quality Assurance & Regulatory Affairs at Correvio LLC and Head-Quality Assurance & Regulatory Affairs at Janssen Pharmaceuticals, Inc.
Robert W. Cook Currently, Robert W. Cook is Chief Financial Officer for CorMedix, Inc. Mr. Cook previously was Chief Financial Officer & Executive Vice President for Pharmos Corp., Chief Financial Officer, Secretary & Treasurer for STRATA Skin Sciences, Inc., Chief Financial Officer, Director & Senior VP at Immune Pharmaceuticals, Inc. and President, CEO, CFO, Secretary & Director at EpiCept Corp. (a subsidiary of Immune Pharmaceuticals, Inc.), Managing Director at The Chase Manhattan Bank NA, Chief Financial Officer at Bioblast Pharma Ltd. and Vice President-Healthcare Group at GE Capital Commercial Finance, Inc. Robert W. Cook received an undergraduate degree from American University.
Elizabeth Masson Elizabeth Masson is Executive Vice President& Head-Clinical Operations at CorMedix, Inc. In her past career she was Vice President-Clinical Operations at Gemphire Therapeutics, Inc. She received an undergraduate degree from Bay Path College.
Phoebe Mounts Phoebe Mounts received a graduate degree from Georgetown University Law Center and a doctorate from The University of Edinburgh.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐